[
  {
    "vignette_index": 1066,
    "input": "Infectious mononucleosis <If both checklist items are 'Yes', append 'END' to signify diagnostic conclusion>",
    "output": "THINKING: Use systematic clinical reasoning to develop a treatment approach for infectious mononucleosis (IM), taking into account the patient's presentation with persistent fatigue, lymphadenopathy, skin rash, and ocular symptoms. Confirming the diagnosis relies on typical clinical features and laboratory testing such as heterophile antibody tests or EBV-specific serologies. IM is usually self-limited, so management focuses on symptomatic relief. The patient's immune status (HIV stage 1) suggests no need for immunosuppression management unless complications arise. The ocular and skin symptoms are likely secondary but warrant monitoring. Care should be coordinated with supportive care, patient education, and appropriate follow-up.\nANSWER: - Primary diagnosis confidence: High, based on clinical features typical of infectious mononucleosis (fatigue, lymphadenopathy, rash, ocular symptoms) and supported by laboratory testing.   - Severity classification: Moderate, given systemic symptoms persisting over three weeks with significant lymphadenopathy and dermatological and ocular manifestations.   - Urgency level: Routine care needed, as the presentation is self-limited but symptom management and monitoring are important.   - Differential considerations still requiring monitoring: Other causes of lymphadenopathy such as lymphoma or other infectious causes, and ocular or skin conditions needing further consultation if symptoms worsen.    STEP 2 - EVIDENCE-BASED TREATMENT SELECTION:   - First-line treatment per guidelines: Symptomatic management with supportive care, including adequate rest, hydration, and analgesics.   - Supporting evidence: No specific antivirals are recommended for uncomplicated IM; symptom relief is the mainstay.   - Patient-specific considerations: The patient\u2019s HIV status requires careful monitoring but does not contraindicate supportive care. The skin rash and ocular symptoms warrant observation for potential secondary complications.   - Contraindications or cautions: Avoid antibiotics like ampicillin if rash develops, and monitor for worsening symptoms indicating complications.  STEP 3 - PHARMACOLOGICAL INTERVENTIONS:   - Primary medication choice: Acetaminophen or NSAIDs (e.g., ibuprofen) for fever, sore throat, and pain.   - Rationale for selection: These medications effectively reduce discomfort and are safe for outpatient management.   - Expected timeline for improvement: Symptoms usually improve within 1-2 weeks, with fatigue gradually resolving over several weeks.   - Key side effects to monitor: Liver function with acetaminophen; gastrointestinal effects and renal function with NSAIDs.   - Alternative medications if first-line fails: None currently indicated; antibiotics are not appropriate unless secondary bacterial infection is diagnosed.  STEP 4 - NON-PHARMACOLOGICAL INTERVENTIONS:   - Primary non-drug interventions: Rest, hydration, good nutrition, avoiding strenuous activities, and limiting contact sports to prevent splenic rupture risk.   - Patient education priorities: Explain the viral etiology, expected course, importance of rest, and avoidance of contact sports for several weeks.   - Lifestyle modifications: Emphasize balanced diet and adequate sleep to support immune recovery.   - Behavioral interventions: Techniques to manage fatigue and stress, including pacing activities.  STEP 5 - MONITORING & FOLLOW-UP STRATEGY:   - Follow-up timeline: Reassess in 1-2 weeks to monitor symptom progression and resolution; longer-term follow-up if symptoms persist or worsen.   - Monitoring parameters: Symptom severity, lymph node size and tenderness, skin rash changes, ocular symptoms, and potential signs of complications such as splenic enlargement.   - Red flag symptoms: Sudden worsening of abdominal pain, high fever, significant abdominal distension, vision changes, or neurological symptoms needing urgent evaluation.   - Treatment response assessment: Symptom relief, reduction in lymphadenopathy, and resolution of rash and ocular symptoms.  STEP 6 - PATIENT COMMUNICATION STRATEGY:   - Communication approach: Use clear, straightforward language emphasizing supportive care, reassurance about typical disease course, and importance of follow-up, while honoring the patient's tangential storytelling.   - Addressing patient concerns: Acknowledge his detailed narrative style, validate concerns, and gently steer conversations toward key points.   - Adherence strategies: Provide written summaries, educate on the importance of rest and hydration, and address misconceptions proactively.   - Family involvement: Discuss the possibility of involving close contacts for support and to improve understanding, if appropriate.  STEP 7 - COORDINATION & REFERRALS:   - Specialist referrals needed: Consider infectious disease if symptoms worsen or do not resolve; ophthalmology consult if ocular symptoms persist or worsen.   - Other healthcare team members: Primary care follow-up and possibly a nutritionist or physical therapist if fatigue persists.   - Community resources: Provide information on support groups for viral illnesses and general health education.   - Insurance/cost considerations: Ensure patient has access to necessary follow-up appointments and understands medication costs.  Based on the diagnosis of infectious mononucleosis, I recommend a comprehensive treatment approach that combines evidence-based medical management with patient-centered care strategies. The treatment plan includes supportive care with analgesics and hydration, rest, and activity modification. Initial management focuses on symptom relief and avoiding activities that could risk splenic injury. Follow-up will be scheduled in 1-2 weeks to monitor symptom resolution, with ongoing assessment for complications. Patient education will emphasize the typical course, signs of worsening, and the importance of limiting strenuous activity. This approach aims to promote recovery, minimize risks, and address the patient's specific presentation and concerns.   - Immediate actions (today): Educate patient on rest, hydration, and symptom management; schedule follow-up.   - Short-term goals (1-4 weeks): Symptom improvement, resolution of rash and ocular symptoms, and reduction in lymphadenopathy.   - Long-term objectives (3-6 months): Complete recovery, monitor for any persistent or recurrent symptoms, and re-evaluate if necessary.   - Patient handout summary: \"Rest and hydrate, take over-the-counter pain relievers as needed, avoid contact sports, follow up as advised, and watch for any new or worsening symptoms.\"",
    "gold_diagnosis": "HIV disease clinical stage 1 without mention of tuberculosis or malaria"
  }
]